
The placenta functions for only nine months but has been taking the science world by storm.
Haifa, Israel-based Pluristem Therapeutics, a key player in the regenerative medicine space is banking on the therapeutic powers of the placenta.
Advertisement
Pluristem takes cells from human placentas that are donated at the time of delivery, and expand and modify them using proprietary 3-dimensional technology and specially designed bioreactors.
The therapeutic cells, coined PLX cells, are designed to be injected into muscle, secrete a range of therapeutic proteins, and then wash out of the body, and do not require any tissue matching.
Pluristem's first cell type, currently in trials, secretes proteins, which could potentially treat certain cardiovascular, and lung diseases, muscle injuries and severe pre-eclampsia, a disease of pregnancy that is one of the leading known causes of maternal death.
Pluristem is now delving into the areas of oncology, bone marrow transplant and even acute radiation syndrome by developing its second product, PLX-R18.
Dr. Karine Kleinhaus highlights the future impact of cell therapy and of PLX-R18 trials underway in 2015.
Source: Medindia
Advertisement
Pluristem's first cell type, currently in trials, secretes proteins, which could potentially treat certain cardiovascular, and lung diseases, muscle injuries and severe pre-eclampsia, a disease of pregnancy that is one of the leading known causes of maternal death.
Pluristem is now delving into the areas of oncology, bone marrow transplant and even acute radiation syndrome by developing its second product, PLX-R18.
Dr. Karine Kleinhaus highlights the future impact of cell therapy and of PLX-R18 trials underway in 2015.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Latest Genetics & Stem Cells News

NGN-401 is a first ever new gene therapy discovered to cure a rare genetic brain disorder called Rett Syndrome.

Among MS patients, the stem cells showed a neuroprotective role, guarding nerve cells from further decline.

New possibilities for research on digestive diseases have been set by complete decoding of the Y chromosome.

UK has given the green light to the world's inaugural gene therapy for sickle-cell disease and thalassemia.

1 in 25 people had a genotype linked to short lifetime, which includes BRCA2 and LDLR genes, that reduced lifespan by seven years, and six years respectively.